Advanced search
Publication Cover
Journal of Medical Economics Volume 24, 2021 - Issue 1
Submit an article Journal homepage
2,828
Views
7
CrossRef citations to date
0
Altmetric
Vaccines

Health and economic burden of invasive pneumococcal disease associated with 15-valent pneumococcal conjugate vaccine serotypes in children across eight European countries

Tianyan Hua Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, USACorrespondence[email protected]
,
Thomas Weissa Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA
,
Goran Bencinab Outcomes Research, MSD, Madrid, SpainORCID Iconhttps://orcid.org/0000-0001-6293-8211
ORCID Icon,
Kwame Owusu-Eduseia Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, USAORCID Iconhttps://orcid.org/0000-0002-4519-2857
ORCID Icon &
Tanaz Petigaraa Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, USAORCID Iconhttps://orcid.org/0000-0001-8366-5101
ORCID Icon
Pages 1098-1107 | Received 03 Sep 2020, Accepted 18 Aug 2021, Published online: 14 Sep 2021

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Josiah Ryman, Jessica Weaver, Ka Lai Yee & Jeffrey R. Sachs. (2022) Predicting effectiveness of the V114 vaccine against invasive pneumococcal disease in children. Expert Review of Vaccines 21:10, pages 1515-1521.
Read now

Articles from other publishers (6)

Salini Mohanty, Bélène Podmore, Ana Cuñado Moral, Ian Matthews, Eric Sarpong, Agueda Azpeitia & Nawab Qizilbash. (2023) Healthcare resource utilisation and cost of pneumococcal disease from 2003 to 2019 in children ≤17 years in England. PLOS ONE 18:4, pages e0283084.
Crossref
Salini Mohanty, Bélène Podmore, Ana Cuñado Moral, Ian Matthews, Eric Sarpong, Alessandra Lacetera & Nawab Qizilbash. (2023) Incidence of pneumococcal disease from 2003 to 2019 in children ≤17 years in England. Pneumonia 15:1.
Crossref
Kristen Feemster & Thomas Weiss. (2022) Letter to the Editor Regarding “Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age”. Infectious Diseases and Therapy 12:1, pages 291-294.
Crossref
Natalie Banniettis, Jacek Wysocki, Leszek Szenborn, Wanatpreeya Phongsamart, Punnee Pitisuttithum, Mika Rämet, Peter Richmond, Yaru Shi, Ron Dagan, Lori Good, Melanie Papa, Robert Lupinacci, Richard McFetridge, Gretchen Tamms, Clay Churchill, Luwy Musey & Kara Bickham. (2022) A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN). Vaccine 40:44, pages 6315-6325.
Crossref
Elisa Barbieri, Gloria Porcu, Tanaz Petigara, Francesca Senese, Gian Marco Prandi, Antonio Scamarcia, Luigi Cantarutti, Anna Cantarutti & Carlo Giaquinto. (2022) The Economic Burden of Pneumococcal Disease in Children: A Population-Based Investigation in the Veneto Region of Italy. Children 9:9, pages 1347.
Crossref
Matt D. Wasserman, Johnna Perdrizet, Lindsay Grant, Kyla Hayford, Shubhra Singh, Paranjoy Saharia, Emily K. Horn & Raymond A. Farkouh. (2021) Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age. Infectious Diseases and Therapy 10:4, pages 2701-2720.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.